Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Belgian biotech company Augustine Therapeutics has successfully raised €78 million (approximately $85 million) in an oversubscribed Series A financing round. The funding was led by Novo Holdings, Jeito Capital, and Asabys Partners, with participation from existing investors including V-Bio and Lilly. This capital will support the advancement of treatments for neuromuscular and cardio-metabolic diseases, particularly focusing on their lead candidate, AGT-100216, which targets Charcot-Marie-Tooth disease. In addition, other companies have also secured funding, including BioCopy, which raised €8 million, Gaia Turbine SA, which obtained €1.15 million for its hydroelectric turbine, and Clee Medical, which received €150,000 from Venture Kick. TheraPPI has also completed pre-seed financing for its lead oncology program.
💡 Belgian startup Augustine Therapeutics secures €77.7M in Series A funding to advance treatments for neuromuscular and cardio-metabolic diseases. Their lead candidate, AGT-100216, targets Charcot-Marie-Tooth disease. Exciting times ahead for biotech! 🌟 https://t.co/NxonJqChSG
Augustine Therapeutics étend à 78 millions d’euros son tour de série A avec Jeito Capital et Novo Holdings. Cette biotech belge s’apprête à lancer les essais cliniques d’un nouveau médicament pour la maladie de Charcot-Marie-Tooth. #PrivateEquity https://t.co/vHSrwdwcUX
Augustine Therapeutics raises oversubscribed €78M /$85M Series A financing round led by Novo Holdings, Jeito Captial, & Asabys Partners (& existing investors V-Bio, Lilly, & others). https://t.co/ydykkZTQVI
